[急性髓系白血病造血干细胞移植的进展]
[Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].
作者信息
Zhu X L, Huang X J, Wang Y
机构信息
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):179-185. doi: 10.3760/cma.j.cn121090-20240422-00157.
Abstract
Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells. Although new drugs have emerged in recent years, the status of hematopoietic stem cell transplantation (HSCT) in AML still remains irreplaceable. This article reviews the adjustment of indications for HSCT in AML, donor selection, and updates of conditioning regimens, new prevention strategies for post-transplant relapse, new targeted drugs, immunotherapy combined with HSCT to improve the prognosis of relapsed and refractory AML, and optimization of transplantation technology for elderly AML.
摘要
急性髓系白血病（AML）是一种髓系造血干/祖细胞的恶性疾病。尽管近年来出现了新的药物，但造血干细胞移植（HSCT）在AML中的地位仍然不可替代。本文综述了AML中HSCT适应证的调整、供者选择、预处理方案的更新、移植后复发的新预防策略、新的靶向药物、免疫治疗联合HSCT改善复发/难治性AML的预后，以及老年AML移植技术的优化。
相似文献
1
[Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].[急性髓系白血病造血干细胞移植的进展]
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):179-185. doi: 10.3760/cma.j.cn121090-20240422-00157.
2
Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.未处理的单倍体相合供者移植与同基因供者相比，对未缓解状态的难治/复发急性髓系白血病有更好的抗白血病效果。
Ann Hematol. 2020 Dec;99(12):2911-2925. doi: 10.1007/s00277-020-04283-0. Epub 2020 Oct 1.
3
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.病例报告：供体衍生的慢性淋巴细胞白血病嵌合抗原受体 T 细胞治疗缓解后复发/难治性急性髓系白血病桥接异基因造血干细胞移植。
Front Immunol. 2024 May 13;15:1389227. doi: 10.3389/fimmu.2024.1389227. eCollection 2024.
4
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关：日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
5
Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.老年急性髓系白血病患者采用不同供者来源造血干细胞移植及分子可测残留病对其预后的影响
Transplant Cell Ther. 2021 Sep;27(9):774.e1-774.e12. doi: 10.1016/j.jtct.2021.05.024. Epub 2021 May 31.
6
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.复发或难治性急性髓系白血病患者异基因造血干细胞移植前合并症的长期随访及影响——来自前瞻性BRIDGE试验的经验教训
Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17.
7
CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.CLAG 联合全身照射作为强化预处理方案，用于治疗难治或复发的急性髓细胞白血病患者的异基因造血干细胞移植。
Ann Hematol. 2024 Jan;103(1):241-249. doi: 10.1007/s00277-023-05502-0. Epub 2023 Oct 17.
8
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.原发性难治性急性髓系白血病异基因造血干细胞移植中匹配同胞供者与无关供者的比较：一项代表 EBMT 急性白血病工作组进行的研究。
J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.
9
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.中华血液学分会关于异基因造血干细胞移植适应证、预处理方案及供者选择的专家共识（2021 年版）
J Hematol Oncol. 2021 Sep 15;14(1):145. doi: 10.1186/s13045-021-01159-2.
10
Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.异基因造血干细胞移植治疗急性髓系白血病的预处理方案。
Bone Marrow Transplant. 2017 Nov;52(11):1504-1511. doi: 10.1038/bmt.2017.83. Epub 2017 May 15.
本文引用的文献
1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
2
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.欧洲 2022 年造血细胞移植和细胞治疗。嵌合抗原受体 T 细胞（CAR-T）治疗持续增长；移植治疗活动放缓：来自 EBMT 的报告。
Bone Marrow Transplant. 2024 Jun;59(6):803-812. doi: 10.1038/s41409-024-02248-9. Epub 2024 Mar 4.
3
TP53 in MDS and AML: Biological and clinical advances.TP53 在 MDS 和 AML 中的作用：生物学和临床进展。
Cancer Lett. 2024 Apr 28;588:216767. doi: 10.1016/j.canlet.2024.216767. Epub 2024 Feb 27.
4
STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2 T cells in acute myeloid leukemia.STAT5 对于诱导急性髓系白血病中 Vδ2 T 细胞的抑制亚群和减弱其细胞毒性是必需的。
Cancer Lett. 2024 Apr 10;587:216730. doi: 10.1016/j.canlet.2024.216730. Epub 2024 Feb 13.
5
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.吉特替尼联合维奈托克、小剂量阿糖胞苷和放线菌素 D 治疗复发/难治性 FLT3 突变型急性髓系白血病。
Br J Haematol. 2024 Apr;204(4):1227-1231. doi: 10.1111/bjh.19318. Epub 2024 Jan 30.
6
[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)].《成人急性髓系白血病（非急性早幼粒细胞白血病）诊断与治疗中国指南（2023年版）》
Zhonghua Xue Ye Xue Za Zhi. 2023 Sep 14;44(9):705-712. doi: 10.3760/cma.j.issn.0253-2727.2023.09.001.
7
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.基因模式对 FLT3-ITD 急性髓系白血病患者接受异基因造血干细胞移植后索拉非尼疗效的影响：一项多中心队列研究。
Signal Transduct Target Ther. 2023 Sep 14;8(1):348. doi: 10.1038/s41392-023-01614-1.
8
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.异基因造血干细胞移植后索拉非尼维持治疗 FLT3-ITD 急性髓系白血病患者：一项开放标签、多中心、随机、3 期临床试验的长期随访。
Lancet Haematol. 2023 Aug;10(8):e600-e611. doi: 10.1016/S2352-3026(23)00117-5. Epub 2023 Jul 3.
9
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.在 HLA 单倍体相合造血细胞移植治疗 AML 中，白消安联合氟达拉滨与白消安联合环磷酰胺的比较：一项多中心随机 III 期试验。
J Clin Oncol. 2023 Oct 10;41(29):4632-4642. doi: 10.1200/JCO.23.00101. Epub 2023 Jun 19.
10
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.嵌合抗原受体自然杀伤细胞疗法治疗血液系统恶性肿瘤：2022 年ASH 年会最新进展。
J Hematol Oncol. 2023 Apr 7;16(1):35. doi: 10.1186/s13045-023-01435-3.
Zotero 插件